Evidence map›Paper›PMID 36568214›Full record

ArticleFrontiers in oncology2022

Construction and validation of a novel web-based nomogram for patients with lung cancer with bone metastasis: A real-world analysis based on the SEER database.

Mengchen Yin, Sisi Guan, Xing Ding, Ruoyu Zhuang, Zhengwang Sun, Tao Wang, Jiale Zheng, Lin Li, Xin Gao, Haifeng Wei and 4 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mengchen YinLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Sisi GuanLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xing DingLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ruoyu ZhuangLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhengwang SunDepartment of Musculoskeletal Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.
Tao WangDepartment of Orthopaedics, The Second Hospital of Anhui Medical University, Anhui, China.
Jiale ZhengLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Lin LiChangzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Xin GaoChangzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Haifeng WeiChangzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Junming MaLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Quan HuangChangzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Jianru XiaoChangzheng Hospital, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Wen MoLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Patients with lung cancer with bone metastasis (LCBM) often have a very poor prognosis. The purpose of this study is to characterize the prevalence and associated factors and to develop a prognostic nomogram to predict the overall survival (OS) and cancer-specific survival (CSS) for patients with LCBM using multicenter population-based data. Methods: Patients with LCBM at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) Program database of the National Cancer Institute (NCI) from 2010 to 2015. Multivariable and univariate logistic regression analyses were performed to identify factors associated with all-cause mortality and lung cancer (LC)-specific mortality. The performance of the nomograms was evaluated with the calibration curves, area under the curve (AUC), and decision curve analysis (DCA). Kaplan-Meier analysis and log-rank tests were used to estimate the survival times of patients with LCBM. Results: We finally identified 26,367 patients with LCBM who were selected for survival analysis. Multivariate analysis demonstrated age, sex, T stage, N stage, grade, histology, radiation therapy, chemotherapy, primary site, primary surgery, liver metastasis, and brain metastasis as independent predictors for LCBM. The AUC values of the nomogram for the OS prediction were 0.755, 0.746, and 0.775 in the training cohort; 0.757, 0.763, and 0.765 in the internal validation cohort; and 0.769, 0.781, and 0.867 in the external validation cohort. For CSS, the values were 0.753, 0.753, and 0.757 in the training cohort; 0.753, 0.753, and 0.757 in the internal validation cohort; and 0.767, 0.774, and 0.872 in the external validation cohort. Conclusions: Our study constructs a new prognostic model and clearly presents the clinicopathological features and survival analysis of patients with LCBM. The result indicated that the nomograms had favorable discrimination, good consistency, and clinical benefits in patients. In addition, our constructed nomogram prediction models may assist physicians in evaluating individualized prognosis and deciding on treatment for patients.

Indexed as

bone metastasescancer-specific survivallung canceroverall survivalSEER

Identifiers

PMID36568214
PMCPMC9780685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.